Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castrationresistant prostate cancer (CRPC) 1 . However, less is known about the role of mutations [2] [3] [4] . Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusionnegative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin-and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Although localized prostate cancer is highly curable, more than 32,000 US men die annually of metastatic disease. Androgen-deprivation therapy results in rapid responses in men with metastatic prostate cancer; however, nearly all patients eventually progress to CRPC. Although CRPC was thought to be androgen-signalling independent, recent evidence demonstrates that androgen signalling is often maintained through varied mechanisms (reviewed in refs 1, 5) . Gene expression and copy number profiling studies have identified recurrent gene fusions, chromosomal gains and losses, and deregulated pathways in prostate cancer 1 . Resequencing studies have characterized the mutational spectrum of prostate cancer 3, 4, 6 , and the genomes of seven localized prostate cancers have been reported 7 . More recently, the exomes of xenografts from 16 CRPC cases were reported 2 .
We sequenced the exomes of 50 lethal heavily pre-treated CRPCs (patient identifiers WA2-WA60) obtained at rapid autopsy 8 , including three distinct sites in the same patient, and 11 treatment-naive, high-grade localized prostate cancers (patient identifiers T1-T97) ( Supplementary Table 1 ). Sequencing results, including coverage statistics, mutation rates, validation rates, mutational spectrum, confirmation of the monoclonal origin of CRPC, and overlap with mutations observed in previous studies are provided in Supplementary Results, Supplementary Figs 1-6 and Supplementary Tables 2-6 .
We used exome sequencing data to identify somatic copy number alterations 9 (see Methods, Supplementary Fig. 7 and Supplementary  Tables 7-9) , and as shown in Supplementary Fig. 8 we identified recurrent aberrations previously associated with prostate cancer development and progression (Supplementary Results). We additionally performed array comparative genome hybridization (aCGH) copy number and gene expression profiling on a matched cohort of benign prostate tissues, localized prostate cancers (3/59 sequenced) and 35 CRPCs (31/35 sequenced) ( Supplementary Table 10 ). Profiles were uploaded into Oncomine (http://www.oncomine.com) for automated data processing, analysis and visualization, and are available for exploration. aCGH profiles were similar to copy number analysis by exome sequencing and to other prostate cancer profiling studies available in Oncomine ( Supplementary Fig. 9 ). Global gene expression profiles were similar to previous studies (analyses available in Oncomine), with exceptions described in Supplementary Results and Supplementary Fig. 10 . Finally, we performed transcriptome sequencing of 11 prostate cancer cell lines to identify likely somatic variants (see Supplementary Results, Supplementary Methods and Supplementary Tables 11-15 ).
From our exome data, we identified nine genes that were significantly mutated (false discovery rate # 0.10) ( Fig. 1 and Supplementary Tables  16 and 4 ), six of which have been reported as recurrently mutated in prostate cancer: TP53, AR, ZFHX3, RB1, PTEN and APC. Three significantly mutated genes do not have described roles in prostate cancer: MLL2, OR5L1 and CDK12. MLL2 encodes a H3K4-specific histone methyltransferase that is recurrently mutated in multiple cancers and CDK12 was recently identified as significantly mutated in ovarian serous carcinoma 10 . Additionally, using several approaches, we identified multiple significantly mutated pathways, including WNT signalling and a PTEN interaction network (Supplementary Fig. 11 and Supplementary Tables 17 and 18 ); observations on significantly mutated genes and pathways are provided in the Supplementary Results. Multiple candidate driver mutations in genes associated with AR signalling, the DNA damage response, histone/chromatin modification, the spindle checkpoint, and classical tumour suppressors and oncogenes were also identified ( Fig. 1 ). For example, we identified two deleterious mutations in PRKDC (I1137 frame shift and E640 non-sense), which encodes the catalytic subunit of the DNA-dependent protein kinase involved in DNA double-strand break repair and recombination, in patient T96, who had an extremely aggressive localized prostate cancer. Additional mutated genes in these pathways are described in Supplementary Results.
To identify potential CRPC drivers, we considered genes with recurrent high-level gains or losses present in peaks of global copy number change, and compared results to mutated genes (Supplementary Fig. 12 ), as described in Supplementary Results. Thus, we were intrigued by the peak of copy number loss on chromosome (chr)5q21 ( Fig. 2a and Supplementary Fig. 12 ) harbouring CHD1, which encodes an ATP-dependent chromatin-remodelling enzyme previously reported as deregulated in 3 of 7 prostate cancer genomes (one somatic splice-site mutation and two rearrangements) 7 
. As described in Supplementary
Results and Supplementary Fig. 13 , across our exome and aCGH copy number analysis, we identified focal deletions or mutations of CHD1 (CHD1 2 ) in 10/119 (8%) prostate cancers, which was significantly associated with ETS gene family fusion-negative (ETS 2 ) status (twosided Fisher's exact test, P 5 0.02). Association of CHD1 gene expression and genomic CHD1 2 status is shown in Supplementary Fig. 13b .
We next analysed the association between CHD1 2 and ETS status in three prostate cancer aCGH and nine expression profiling studies (totalling 835 additional cancers) using Oncomine (Supplementary Results). As shown in Supplementary Fig. 14 Supplementary Table  19 and Fig. 2b , in total, across 13 DNA-and RNA-based studies, we identified 50 of 954 (5.2%) prostate cancers as CHD1 2 , 48 of which (96%) were ETS 2 (P , 0.0001, two-sided Fisher's exact test). Together, our integrated analysis identifies CHD1 2 /ETS 2 as a novel prostate cancer subtype.
ETS genes have a central role in prostate cancer, most commonly through fusion to androgen-driven genes (that is, TMPRSS2:ERG), and as the majority of ETS gene family fusion-positive (ETS 1 ) CRPCs retained marked overexpression of the rearranged ETS gene 
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(ERG, ETV1 or ETV5), our results support active androgen signalling in the majority of these men ( Supplementary Fig. 13b ). We next further explored the role of ETS genes in prostate cancer by evaluating our data set for aberrations in additional ETS genes. Importantly, two CRPCs harboured deleterious mutations in ETV3 (P327fs in WA56 and W38* in WA26, both ETS 1 ), which does not have a described role in prostate cancer. In addition, we were intrigued by the mutation of ETS2 (R437C) in WA30 (ETS 2 ), as ETS2 shows a similar DNA binding motif as ERG 11 and is located immediately telomeric to ERG (head-to-head orientation) in the commonly deleted region in TMPRSS2:ERG fusions through deletion. We also identified focal deletions extending telomerically from ERG in ERG-rearranged cancers, as well as focal deletion of ETS2 in WA31, which shows outlier underexpression of ETS2 (Supplementary Results and Supplementary  Fig. 15 ). Additionally, the R437C mutation in ETS2 occurs in the ETS domain at a DNA-contacting residue conserved in class I ETS transcription factors 11 , which include all ETS genes known to be involved in gene fusions in prostate cancer (Fig. 2c ). Given observations that prostate cancers with TMPRSS2:ERG fusions through deletion may be more aggressive than those with fusions through insertion, we and others have speculated that the intervening region may harbour tumour suppressors, including ETS2 [12] [13] [14] . As shown in Fig. 2d , we demonstrate that overexpression of wild-type ETS2 results in decreased migration, invasion and proliferation in VCaP (ERG 1 CRPC, active AR signalling) cells, whereas the R437C mutation has opposite effects, supporting a potential tumour suppressive role for ETS2.
In addition to MLL2 and CHD1, our integrated analysis identified mutations and copy number aberrations in multiple other genes involved in chromatin/histone modification (Fig. 1) , including several members of the MLL complex (see Supplementary Results and Fig. 3 ). Only samples with at least one gene in the region with a called copy number gain/loss are shown, and missing boxes indicate that gene has no called copy number gain/loss. Mutations in CHD1 are indicated according to the legend and samples with focal deletions or mutation of CHD1 are in bold. b, Co-occurrence of CHD1 deregulation (CHD1 2 ) and ETS 1 from the current exome study and three aCGH studies (Exome/aCGH), nine gene expression profiling studies (Gene expr.), and all studies (All). The total number of samples in each set (n) is shown, and two-sided Fisher's exact tests were performed. c, d, ETS2 is a prostate cancer tumour suppressor deregulated through deletion and mutation. c, WA30 (yellow) harboured a R437C mutation that disrupts a residue conserved in class I ETS transcription factors (red), but not in class IIb or III factors (blue and black, respectively). Amino acid residue numbering is shown above the domain structure. R437 (yellow) contacts DNA (blue and magenta) in the ETS domain (brown), as shown by the structure of the homologous residue in ETS1 (R409, PDB accession 3MFK 23 ). d, VCaP prostate cancer cells (ERG 1 ) stably expressing ETS2 (wild type or R437C) or LACZ were evaluated for migration (left panel, n 5 8), invasion (middle panel, n 5 12) and proliferation (right panel, n 5 4). For migration and invasion, fold change relative to VCaP LACZ was plotted. For each experiment, mean 6 standard error is plotted; *P , 0.05, **P , 0.001 from two-tailed t-tests. modifiers that physically interact with the AR. a-c, Deregulation through mutation or high-level copy aberrations of multiple chromatin/histone modifying genes was identified (see Fig. 1 ). a, Interaction of deregulated chromatin/histone modifiers with the AR. AR (or IgG as control) was immunoprecipitated (IP) from VCaP cells and western blotting for the indicated chromatin/histone modifier was performed. Lysate (1%) was used as control. EZH2 and FOXA1 were used as negative and positive controls, respectively. b, VCaP cells were treated with siRNAs against MLL or ASH2L (or non-targeting as control), starved, stimulated with vehicle or 1 nm R1881 for the indicated times and harvested. Quantitative polymerase chain reaction (PCR) for KLK3 expression (relative to vehicle) is plotted (n 5 3, mean 1 standard error). c, Summary of genes interacting with the AR that are deregulated in CRPC. Frequency of high copy alterations, somatic mutations, and both aberration types according to the colour scales, are shown for chromatin/histone modifiers, the AR collaborating factor FOXA1 and ERG. MLL aberration frequency includes MLL, MLL2, MLL3 and MLL5. Genes encoding AR interactors identified in this and previous studies are indicated by bold and regular arrows, respectively.
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Besides CHD1, which shows deregulation in both localized prostate cancer and CRPC ( Fig. 2 and Supplementary Figs 13 and 14) , mutations of other chromatin/histone remodelling genes were infrequent in localized prostate cancer and concentrated in a single sample (T97; Fig. 1 ). Hence, we hypothesized that the mutated chromatin/histone remodellers we identified may mediate AR signalling through interaction. Thus, we immunoprecipitated endogenous AR from VCaP cells and blotted for members of the MLL complex (MLL2, MLL, ASH2L), UTX, ASXL1 and CHD1. FOXA1, a known direct interacting AR cofactor 15 , and EZH2 (a H3K27 histone methyltransferase overexpressed in CRPC), were evaluated as positive and negative controls, respectively. As shown in Fig. 3a , members of the MLL complex, UTX and ASXL1 all interact with AR, whereas interaction with CHD1 was not observed. Reverse immunoprecipitation confirmed interactions between AR and MLL, MLL2, ASH2L and FOXA1 ( Supplementary  Fig. 16a ).
As the MLL complex is implicated in epigenetic transcriptional activation, we studied its role in AR signalling. RNA interference of MLL or ASH2L using independent short interfering (si)RNAs ( Supplementary Fig. 16b ) significantly inhibited AR signalling, as assessed by inhibition of R1881 (synthetic androgen) stimulation of KLK3 (also known as PSA) expression, with two siRNAs each against MLL or ASH2L inhibiting KLK3 expression at 24 h by .7.5 fold (each P , 0.001) (Fig. 3b ). Together, our data suggest that aberrations in AR For each FOXA1 mutant (or wild-type) DHT/vehicle condition, the percentage of filtered probes showing ,1.5 or .21.5 fold change (indicating repression) is indicated. NA, probe did not pass filtering. e, Subcutaneous xenografts were generated from LNCaP cells (control, purple, n 5 6), or LNCaP cells stably expressing N-terminally HA-tagged FOXA1 (wild type (n 5 9) or S453fs (n 5 10)). Tumour volume is plotted and representative tumours are shown. Mean 1 standard error is plotted; *P , 0.05 from two-tailed t-test.
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and interacting proteins, including chromatin/histone remodellers, ETS genes (exemplified by ERG, whose encoded product directly interacts with AR 16 ) and known AR co-regulators including FOXA1 (see below), are common in CRPC (Fig. 3c) .
Given the central role of AR signalling in CRPC and the selection for aberrations in AR occurring in CRPC, we were intrigued by the identification of a somatic 2-base-pair insertion in FOXA1 (S453fs) in the localized prostate cancer sample T12, and 340fs and P358fs indels in DU-145 and LAPC-4 (identified by transcriptome sequencing), respectively, given the well described role of FOXA1 in AR signalling [17] [18] [19] [20] [21] [22] . Thus, we screened 101 localized and 46 CRPCs (including foci from all exome sequenced CRPCs), and identified somatic mutations of FOXA1 in four localized prostate cancers and one CRPC (total 5 of 147, 3.4%). Importantly, 4 of the 5 mutations, as well as both indels identified in the transcriptome screen, occurred in the carboxyterminal transactivating domain (Fig. 4a ).
As described in Supplementary Results, we demonstrate that stable expression in LNCaP (ETV1 1 CRPC, active AR signalling) cells of either wild-type FOXA1 or observed FOXA1 mutants increases proliferation in the presence of androgen (Fig. 4b, c ), represses the AR transcriptional program (Fig. 4d ), and results in increased soft agar colony ( Supplementary Fig. 17 ) and xenograft growth (Fig. 4e ).
Our integrated, exome-based profiling of the mutational landscape of CRPC is notable for representing a large cohort of heavily pre-treated patients with lethal metastatic disease, which are not commonly studied, and provides insights into the resistance mechanisms that evolve in refractory tumours. Additionally, we identified a diverse series of potentially driving mutations and copy number alterations in both known and novel genes and pathways, including FOXA1. Finally, our integrative genomics data set provides a useful resource for the study of lethal prostate cancer, as well as determinants of, or resistance mechanisms to, radiation and chemotherapy.
METHODS SUMMARY
See Supplementary Methods for source of prostate tissues and cell lines, nucleic acid isolation, exome and transcriptome sequencing and data analysis, mutation validation by Sanger sequencing, aCGH and DNA microarray expression profiling, ETS2 in vitro experiments, AR interactor immunoprecipitation, western blotting, siRNA experiments, FOXA1 screening and in vitro and in vivo experiments.
